Stocktoria
MEDIFAST INC MED
MEDIFAST INC financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $385.8M | $602.5M | $1.1B | $1.6B | $1.5B | $934.8M | $713.7M | $501.0M | $301.6M | $274.5M |
| Gross profit | $275.2M | $444.6M | $775.9M | $1.1B | $1.1B | $697.8M | $536.9M | $379.9M | $227.8M | $205.7M |
| R&D expense | $4.3M | $4.6M | $4.6M | $4.5M | $4.4M | $2.8M | $2.7M | $2.2M | $1.5M | $2.0M |
| SG&A expense | $289.4M | $441.7M | $649.4M | $955.6M | $911.4M | $563.7M | $445.8M | $310.8M | $188.2M | $178.8M |
| Operating income | -$14.2M | $2.9M | $126.4M | $184.8M | $216.2M | $134.2M | $91.0M | $69.1M | $39.6M | $26.9M |
| Income tax | $13.0M | $1.7M | $29.4M | $40.5M | $52.1M | $31.4M | $14.4M | $14.8M | $12.6M | $9.3M |
| Net income | -$18.7M | $2.1M | $99.4M | $143.6M | $164.0M | $102.9M | $77.9M | $55.8M | $27.7M | $17.8M |
| EPS (diluted) | $-1.70 | $0.19 | $9.10 | $12.73 | $13.89 | $8.68 | $6.43 | $4.62 | $2.29 | $1.49 |
| Operating cash flow | $6.9M | $24.5M | $147.7M | $194.6M | $94.5M | $145.2M | $84.3M | $60.8M | $43.2M | $26.0M |
| Free cash flow | $1.2M | $17.0M | $141.2M | $177.9M | $60.3M | $139.3M | $74.2M | $55.9M | $40.0M | $23.1M |
| Cash & equivalents | $89.3M | $90.9M | $94.4M | $87.7M | $104.2M | $163.7M | $77.0M | $81.4M | $75.1M | $52.4M |
| Inventory | $20.2M | $42.4M | $54.6M | $118.9M | $180.0M | $53.4M | $48.8M | $38.9M | $19.3M | $18.3M |
| Total assets | $248.0M | $284.2M | $309.9M | $316.2M | $398.3M | $276.1M | $194.7M | $169.4M | $145.9M | $121.2M |
| Total liabilities | $49.1M | $74.1M | $108.4M | $161.2M | $195.9M | $118.8M | $89.8M | $60.3M | $37.3M | $25.2M |
| Shareholders' equity | $198.9M | $210.1M | $201.5M | $155.0M | $202.5M | $157.2M | $104.8M | $109.1M | $106.6M | $96.0M |
Growth · year-over-year · Revenue CAGR 3.9%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -36.0% | -43.8% | -32.9% | +4.8% | +63.2% | +31.0% | +42.4% | +66.1% | +9.8% | +0.6% |
| Net income growth | -993.0% | -97.9% | -30.8% | -12.5% | +59.5% | +32.0% | +39.7% | +101.3% | +55.4% | -11.1% |
| EPS growth | -994.7% | -97.9% | -28.5% | -8.4% | +60.0% | +35.0% | +39.2% | +101.7% | +53.7% | -10.2% |
| Free cash flow growth | -92.7% | -87.9% | -20.6% | +194.8% | -56.7% | +87.7% | +32.8% | +39.7% | +73.0% | -23.7% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.